CN109568312A - 用于治疗癌症的化合物 - Google Patents

用于治疗癌症的化合物 Download PDF

Info

Publication number
CN109568312A
CN109568312A CN201811371741.5A CN201811371741A CN109568312A CN 109568312 A CN109568312 A CN 109568312A CN 201811371741 A CN201811371741 A CN 201811371741A CN 109568312 A CN109568312 A CN 109568312A
Authority
CN
China
Prior art keywords
cancer
another embodiment
compound
alkyl
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811371741.5A
Other languages
English (en)
Chinese (zh)
Inventor
J·王
陈建军
D·D.·米勒
李伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of CN109568312A publication Critical patent/CN109568312A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201811371741.5A 2013-03-05 2014-03-05 用于治疗癌症的化合物 Pending CN109568312A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361772885P 2013-03-05 2013-03-05
US61/772,885 2013-03-05
CN201480025267.4A CN105163584B (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480025267.4A Division CN105163584B (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物

Publications (1)

Publication Number Publication Date
CN109568312A true CN109568312A (zh) 2019-04-05

Family

ID=51491914

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811371741.5A Pending CN109568312A (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物
CN201480025267.4A Active CN105163584B (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480025267.4A Active CN105163584B (zh) 2013-03-05 2014-03-05 用于治疗癌症的化合物

Country Status (11)

Country Link
US (2) US10022356B2 (enExample)
EP (1) EP2964028A4 (enExample)
JP (2) JP6835472B2 (enExample)
KR (1) KR102246652B1 (enExample)
CN (2) CN109568312A (enExample)
AU (2) AU2014225761B2 (enExample)
CA (1) CA2904338C (enExample)
IL (1) IL241232B (enExample)
MX (2) MX375059B (enExample)
RU (1) RU2708247C2 (enExample)
WO (1) WO2014138279A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2010074776A2 (en) * 2008-06-16 2010-07-01 The University Of Tennessee Research Foundation Compounds for the treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
AU2014225761B2 (en) 2013-03-05 2018-06-07 University Of Tennessee Research Foundation Compounds for treatment of cancer
ES2815374T3 (es) 2014-05-06 2021-03-29 Oncternal Therapeutics Inc Compuestos para el tratamiento del cáncer
CN104434924B (zh) * 2014-11-10 2016-09-14 暨南大学 曲美替尼在制备逆转肿瘤多药耐药性药物中的应用
US20190117652A1 (en) * 2014-12-23 2019-04-25 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and taxanes
US10792284B2 (en) 2015-02-12 2020-10-06 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment
IL256111B2 (en) * 2015-06-05 2023-09-01 Univ Illinois Treatment of pac combinations
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
JP2018520164A (ja) * 2015-07-09 2018-07-26 ザ ジャクソン ラボラトリー プロテアソームインヒビターと組み合わせてｍｅｋインヒビターを投与することによりがんを処置する方法
US20180228740A1 (en) * 2015-08-06 2018-08-16 The Wistar Institute Of Anatomy And Biology Combination therapies targeting mitochondrial biogenesis for cancer therapy
US10821112B2 (en) 2016-03-16 2020-11-03 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
WO2017200826A1 (en) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Assays and compounds for treatment of cancer
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
EP3594357A4 (en) 2017-03-10 2020-03-11 Konica Minolta, Inc. METHOD OF ESTIMATING THERAPEUTIC EFFICACY
EP3618807A4 (en) * 2017-05-03 2021-01-20 Jian Zuo COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
SG11202004384YA (en) 2017-11-17 2020-06-29 Univ Illinois Cancer therapy by degrading dual mek signaling
CN108218855A (zh) * 2018-03-12 2018-06-29 桑文军 一种新型微管蛋白抑制剂及其在抗肿瘤药物中的应用
CN112437664A (zh) * 2018-05-15 2021-03-02 田纳西大学研究基金会 用于治疗胰腺癌的化合物
KR20210020022A (ko) * 2018-05-15 2021-02-23 유니버시티 오브 테네시 리서치 파운데이션 삼중 음성 유방암 및 난소암 치료용 화합물
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
GB201913124D0 (en) 2019-09-11 2019-10-23 Seald As Compositions and methods for treatment of cholangiocarcinoma
CA3168648A1 (en) * 2020-01-31 2021-08-05 Verastem, Inc. Combination therapy for treating abnormal cell growth
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
US20230355581A1 (en) * 2020-07-02 2023-11-09 The Board of Regents of the Unversity of Texas System Methods of treatment for melanoma
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects
WO2022131667A1 (ko) * 2020-12-18 2022-06-23 경희대학교 산학협력단 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
CN115504964A (zh) * 2022-04-12 2022-12-23 海创药业股份有限公司 氘代杂环酮类化合物及其用途
CN117143081B (zh) * 2022-05-24 2025-08-01 赣南医科大学 一种Sabizabulin的制备方法
WO2024036114A2 (en) * 2022-08-08 2024-02-15 The Regents Of The University Of California Combination therapy including cox-2 inhibitor for the treatment of cancer
WO2024186641A1 (en) * 2023-03-03 2024-09-12 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
CN119409641A (zh) * 2024-11-05 2025-02-11 杭州电子科技大学 一种磺酰基衍生物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102883607A (zh) * 2010-03-01 2013-01-16 Gtx公司 用于治疗癌的化合物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
DK1130017T3 (da) 1990-11-30 2005-10-10 Otsuka Pharma Co Ltd Azolderivater og deres anvendelse som superoxidradikalinhibitorer
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
JP2550915B2 (ja) 1994-06-21 1996-11-06 日本電気株式会社 印刷配線板の表面保護剤および表面保護膜の形成方法
DE60117605T2 (de) 2000-12-21 2006-12-07 Bristol-Myers Squibb Co. Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
WO2003027101A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl pyrroles and 3-pyridyl pyrazoles as c17,20 lyase inhibitors
US20040267017A1 (en) 2001-09-26 2004-12-30 Bierer Donald E 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
EP1456187A4 (en) 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
EP1594847A2 (en) 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
CA2523808A1 (en) 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
MXPA06005528A (es) 2003-11-18 2007-01-30 Univ Tennessee Res Foundation Tiazolidinona-amidas, amidas de acido tiazolidina-carboxilico, metodos de elaboracion, y uso de las mismas.
EP2284157A1 (en) 2003-12-12 2011-02-16 Wyeth Quinolines useful in treating cardiovascular disease
BRPI0508594A (pt) 2004-03-08 2007-08-21 Wyeth Corp moduladores de canal de ìon
CA2584493A1 (en) * 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
PL1893612T3 (pl) * 2005-06-22 2012-01-31 Plexxikon Inc Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
US7464893B2 (en) * 2006-06-30 2008-12-16 Per Spjut Method of using a cord holder
KR100932093B1 (ko) 2006-09-27 2009-12-16 주식회사종근당 미세소관 형성 저해제로서 유용한 벤조페논 유도체
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
WO2010074776A2 (en) 2008-06-16 2010-07-01 The University Of Tennessee Research Foundation Compounds for the treatment of cancer
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DK4159217T3 (da) 2009-10-16 2024-08-12 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
WO2012027716A1 (en) * 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
KR101418229B1 (ko) 2011-03-29 2014-07-09 미쓰비시덴키 가부시키가이샤 서보 제어 장치의 이상 진단 장치 및 이상 진단 시스템
RS56759B2 (sr) * 2011-04-01 2024-10-31 Genentech Inc Kombinacija akt inhibitor jedinjenja i abiraterona za upotrebu pri terapeutskim tretiranjima
EP2694510B1 (en) 2011-04-07 2015-10-14 Bayer Intellectual Property GmbH Imidazopyridazines as akt kinase inhibitors
AU2014225761B2 (en) 2013-03-05 2018-06-07 University Of Tennessee Research Foundation Compounds for treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102883607A (zh) * 2010-03-01 2013-01-16 Gtx公司 用于治疗癌的化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANNA TESEI 等: ""Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models", 《JOURNAL OF CELLULAR AND MOLECULAR MEDICINE》 *
SAPNA P. PATEL等: "Clinical Responses to Selumetinib (AZD6244; ARRY-142886)-Based Combination Therapy Stratified by Gene Mutations in Patients With Metastatic Melanoma", 《CANCER》 *

Also Published As

Publication number Publication date
US20180325872A1 (en) 2018-11-15
CA2904338C (en) 2022-07-05
RU2015142102A (ru) 2017-04-07
KR102246652B1 (ko) 2021-04-29
CA2904338A1 (en) 2014-09-12
MX2020009256A (es) 2020-10-28
US10022356B2 (en) 2018-07-17
CN105163584B (zh) 2019-06-04
AU2018226470A1 (en) 2018-09-27
IL241232B (en) 2021-02-28
US10525037B2 (en) 2020-01-07
EP2964028A1 (en) 2016-01-13
IL241232A0 (en) 2015-11-30
JP2016510748A (ja) 2016-04-11
RU2708247C2 (ru) 2019-12-05
JP6835472B2 (ja) 2021-02-24
MX375059B (es) 2025-03-06
EP2964028A4 (en) 2017-06-07
CN105163584A (zh) 2015-12-16
AU2014225761A1 (en) 2015-10-08
RU2015142102A3 (enExample) 2018-03-13
US20160015688A1 (en) 2016-01-21
JP2019077727A (ja) 2019-05-23
MX2015011713A (es) 2016-05-09
AU2018226470B2 (en) 2019-11-28
WO2014138279A1 (en) 2014-09-12
KR20150123328A (ko) 2015-11-03
AU2014225761B2 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
CN105163584B (zh) 用于治疗癌症的化合物
CN110072528B (zh) 治疗肿瘤的药物组合物
CN109069504B (zh) 氨基噻唑化合物及其用途
JP5662321B2 (ja) 骨髄腫の治療のための置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンの使用
TW202019407A (zh) Bcl-2抑制劑與MDM2抑制劑的組合產品及其在預防及/或治療疾病中的用途
TWI726362B (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用
JP2015536986A (ja) 併用療法
CN104436194B (zh) 具有协同增效作用的抗癌组合物
CN114867622A (zh) 涉及二芳基巨环化合物的组合疗法
JPWO2008001886A1 (ja) オーロラ（Ａｕｒｏｒａ）阻害剤
JP2018534314A5 (enExample)
US20180250261A1 (en) Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
JP2019519573A (ja) がんを処置するための方法
JP6239103B2 (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
CN108473504B (zh) 新型二氢吡喃并嘧啶酮衍生物及其用途
AU2017235350B2 (en) Combination therapy for proliferative diseases
JP2017509675A (ja) 癌を処置するためのセファロスポリンの新規誘導体
CN120813358A (zh) 用于治疗肿瘤的药物组合物
JP2019014685A (ja) 抗がん剤
HK40005718A (en) Compounds for treatment of cancer
US20240238220A1 (en) Methods for treating cancers
JP2012087118A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005718

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20190405

RJ01 Rejection of invention patent application after publication